Abstract
Mitomycin C is being used as an adjunct to ionizing radiation in the treatment of some solid tumors. A rationale for this is that radioresistant hypoxic cells in solid tumors will have enhanced sensitivity to this bioreductively activated drug, compared to aerobic cells. The role of oxygen concentration and enzymatic drug reduction in bioreductive drug activation have been investigated. Techniques are reviewed for thein vitro determination of the oxygen concentration dependency of bioreductive drug activation. One of these techniques, an open cell suspension system using Chinese hamster ovary cells, is described. Results are shown that indicate that the oxygen concentration dependency of toxicity of mitomycin C and one of its analogues porfiromycin, though qualitatively complementing the oxygen dependency of ionizing radiation toxicity, are not quantitatively optimal. Using a mitomycin C resistant human cell strain (3437T) from a cancer prone family, a possible role for DT-diaphorase, an oxygen insensitive 2-electron transfer enzyme, is suggested. A correlation between a low level of DT-diaphorase in 3437T cells and mitomycin C resistance under aerobic exposure conditions is seen. Under hypoxic exposure conditions this resistance is lost, suggesting 1-electron transfer enzymes control hypoxic cell bioreductive activation. An activation role for DT-diaphorase in mitomycin C toxicity in the treatment of solid tumors is contrasted to a potential detoxification role for the enzyme with other xenobiotics in the cancer prone family phenotype.
Similar content being viewed by others
References
Suit HD, Miralbell R: Potential impact of improvements in radiation therapy on quality of life and survival. Int J Radiat Oncol Biol Phys 16: 891–895, 1989
Bush RS: Malignancies of the Ovary, Uterus and Cervix. Edward Arnold Ltd, 1979
Moulder JE, Rockwell S: Tumour hypoxia: its impact on cancer therapy. Cancer Metastasis Rev 5: 313–341, 1987
Urtasun RC, Chapman JD, Raleigh JA, Franko AJ, Koch CJ: Binding of3H-misonidazole to solid human tumors as a measure of tumor hypoxia. Int J Radiat Oncol Biol Phys 12: 1263–1269, 1987
Dische S: Keynote address: Hypoxic cell sensitizers: clinical developments. Int J Radiat Oncol Biol Phys 16: 1057–1060, 1989
Jain RK: Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Nat Cancer Inst 81: 570–576, 1989
Fowler JF, Adams GE, Denekamp J: Radiosensitizers of hypoxic cells in solid tumors. Cancer Treat Rev 3: 227–256, 1976
Wardman P: The use of nitroaromatic compounds as hypoxic cell radiosensitizers. Current Topics in Rad Res Quarterly 11: 347–398, 1977
Dische S: Chemical sensitizers for hypoxic cells-a decade of experience in clinical radiotherapy. Radiother Oncol 3: 97–115, 1985
Overgaard J, Hansen HS, Andersen AP, Hjelm-Hansen M, Jorgensen K, Sandberg E, Berthelsen A, Hammer R, Pedersen M: Misonidazole combined with radiotherapy in the treatment of carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys Suppl 16: 1065–1068, 1989
Overgaard J, Sand Hansen H, Lindeløv B, Overgaard M, Jorgensen K, Rasmusson B: Nimorazole as a hypoxic radiosensitizer in the treatment of supraglottic larynx and pharynx carcinoma. First report from the Danish Head And Neck Cancer Study (DAHANCA) protocol 5-85. Radiotherapy Oncology Suppl 20: 143–149, 1991
Sutherland RM: Selective chemotherapy of noncycling cells in anin vitro tumor model. Cancer Res 34: 3501–3503, 1974
Hall EJ, Roizin-Towle L: Hypoxic sensitizer: radiobiological studies at the cellular level. Radiology 117: 453–457, 1975
Moore BA, Palcic B, Skarsgard LD: Radiosensitizing and toxic effects of the 2-nitroimidazole Ro-07-0582 in hypoxic mammalian cells. Radiat Res 67: 459–473, 1976
Taylor YC, Rauth AM: Differences in the toxicity and metabolism of the 2-nitroimidazole misonidazole (Ro-07-0582) in HeLa and Chinese hamster ovary cells. Cancer Res 38: 2745–2752, 1978
Rauth AM: Pharmacology and toxicology of sensitizers: mechanism studies. Int J Radiat Oncol Biol Phys 10: 1293–1300, 1984
Rockwell S, Kennedy KA: Combination therapy with radiation and mitomycin C: preliminary results with EMT6 tumor cellsin vitro andin vivo. Int J Radiat Biol Phys 5: 1673–1676, 1979
Sartorelli AC: Presidential address: Therapeutic attack of hypoxic cells of solid tumors. Cancer Res 48: 775–778, 1988
Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee LL: SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 12: 1239–1242, 1986
Brown JM: Redox activation of benzotriazine N-oxides: mechanisms and potential as anticancer drugs. In: Adams GE, Breccia A, Fielden EM, Wardman P (eds) Selective Activation of Drugs by Redox Processes. Plenum Press, London, 1990, pp137–148
Kennedy KA, Rockwell S, Sartorelli AC: Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumor cells. Cancer Res 40: 2356–2360, 1980
Rauth AM, Mohindra JK, Tannock IF: Activity of mitomycin C for aerobic and hypoxic cellsin vitro andin vivo. Cancer Res 43: 4154–4158, 1983
Powis G: Free radical formation by antitumor quinones. Free Rad Biol Med 6: 63–110, 1989
Laderoute K, Wardman P, Rauth AM: Molecular mechanisms for the hypoxia-dependent activation of 3-ami-no-1,2,4-benzotriazine-1,4-dioxide (SR4233). Biochemical Pharmacol 37: 1487–1495, 1988
Boag JW: Oxygen diffusion and oxygen depletion problems in radiobiology. In: Ebert M, Howard A (eds) Current Topics in Radiation Research, V. North-Holland Pub, Amsterdam, 1969, pp141–195
Chapman JD, Sturrock J, Boag JW, Crookall JO: Factors affecting the oxygen tension around cells growing in plastic Petri dishes. Int J Radiat Biol 17: 305–328, 1970
Young SD: Hypoxia and Cancer Metastasis. Ph.D. Thesis, University of Toronto, 1990
Whillans DW, Rauth AM: An experimental and analytical study of oxygen depletion in stirred cell suspensions. Radiat Res 84: 97–114, 1980
Marshall RS, Koch CJ, Rauth AM: Measurement of low levels of oxygen and their effect on respiration in cell suspensions maintained in an open system. Radiat Res 108: 91–101, 1986
Fengler JJP: Respiration-induced oxygen gradients in cultured mammalian cells. M.Sc. Thesis, University of British Columbia, 1988
Jones DP, Aw TY, Shan X: Characteristics of hypoxic cells that enhance their susceptibility to chemical injury. In: Adams GE, Breccia A, Fielden EM, Wardman P (eds) Selective Activation of Drugs by Redox Processes. Plenum Press, London, 1990, pp1–9
Koch CJ: A thin-film culturing technique allowing rapid gasliquid equilibration (6sec.) with no toxicity to mammalian cells. Radiat Res 97: 434–442, 1984
Rauth AM, Marshall RS: Mechanisms of activation of mitomycin C and AZQ in aerobic and hypoxic mammalian cells. In: Adams GE, Breccia A, Fielden EM, Wardman P (eds) Selective Activation of Drugs by Redox Processes. Plenum Press, London, 1990, pp113–123
Marshall RS, Rauth AM: Modification of the cytotoxic activity of mitomycin C by oxygen and ascorbic acid in Chinese hamster ovary cells and a repair deficient mutant. Cancer Res 46: 2709–2713, 1986
Marshall RS, Rauth AM: Oxygen and exposure kinetics as factors influencing the cytotoxicity of porfiromycin, a mitomycin C analogue, in Chinese hamster ovary cells. Cancer Res 48: 5655–5659, 1988
Keyes SR, Rockwell S, Sartorelli AC: Porfiromycin as a bioreductive alkylating agent with selective toxicity to hypoxic EMT6 tumor cellsin vivo andin vitro. Cancer Res 45: 3642–3645, 1985
Rockwell S, Keyes SR. Sartorelli AC: Preclinical studies of porfiromycin as an adjunct to radiotherapy. Radiat Res 116: 100–113, 1988
Rockwell S, Nierenburg M, Irvin CG: Effects of the mode of administration of mitomycin on tumor and marrow response and on the therapeutic ratio. Cancer Treat Rep 71: 927–934, 1987
Rockwell S, Sartorelli AC: Mitomycin C and radiation. In: Hill BT, Bellamy AS (eds) Antitumor Drug Radiation Interactions. CRC Press Inc, Boca Raton Florida, 1990, pp125–139
Taylor YC, Rauth AM: Oxygen tension, cellular respiration, and redox state as variables influencing the cytotoxicity of the radiosensitizer misonidazole. Radiat Res 91: 104–123, 1983
Silva ML: One-electron versus two-electron bioreductive cytotoxic mechanisms for hypoxic selective anticancer drugs. Ph.D. Thesis, University of Toronto, 1992
Paterson MC, Middlestadt MV, Weinfeld M, Mirzayans R, Gentner NE: Human cancer-prone disorders, abnormal carcinogenesis response, and defective DNA metabolism. In: Burns FJ, Upton AC, Silini G (eds) Radiation Carcinogenesis and DNA Alterations. Plenum Press, New York, 1986, pp471–498
Marshall RS, Paterson MC, Rauth AM: Deficient activation by a human cell strain leads to mitomycin C resistance under aerobic but not hypoxic conditions. Br J Cancer 59: 341–346, 1989
Dorr RT, Liddil JD, Trent JM: Mitomycin C resistant L-1210 leukemia cells: association with pleiotropic drug resistance. Biochem Pharmacol 36: 3115–3120, 1987
Hoban PR, Robson CN, Davies SM, Hall AG, Catton AR, Hickson ID, Harris AL: Reduced topoisomerase II and elevated α class glutathione S-transferase expression in a multidrug resistant CHO cell line highly cross-resistant to mitomycin C. Biochem Pharmacol 43: 685–693, 1992
Keyes SR, Fracasso PM, Heimbrook DC, Rockwell S, Sligar SG, Sartorelli AC: Role of NADPH: cytochrome C reductase and DT-diaphorase in the biotransformation of mitomycin C. Cancer Res 44: 5638–5643, 1984
Pristos CA, Sartorelli AC: Generation of reactive oxygen radicals through bioactivation of mitomycin antibiotics. Cancer Res 46: 3528–3532, 1986
Marshall RS, Paterson MC, Rauth AM: Studies on the mechanism of resistance to mitomycin C and porfiromycin in a human cell strain derived from a cancer-prone individual. Biochem Pharmacol 41: 1351–1360, 1990
Jaiswal A, McBride OW, Adesnik M, Nebert DW: Human dioxin-inducible cytosolic NAD(P)H: menadione oxidoreductase cDNA sequence and localization of gene to chromosome 16. J Biol Chem 263: 13572–13578, 1988
Jaiswal AK, Burnett P, Adesnik M, McBride OW: Nucleotide and deduced amino acid sequence of human cDNA (NQO2) corresponding to a second member of the NAD(P) H:quinone oxidoreductase gene family. Extensive polymorphism at the NQO2 gene locus on chromosome 6. Biochemistry 29: 1899–1906, 1990
Jaiswal AK: Human NAD(P)H:quinone oxidoreductase (NQO1) gene structure and induction by dioxin. Biochemistry 30: 10647–10653, 1991
Dulhanty AM, Li M, Whitmore GF: Isolation of Chinese hamster ovary cell mutants deficient in excision repair and mitomycin C bioactivation. Cancer Res 49: 117–122, 1989
Dulhanty AM, Whitmore GF: Chinese hamster ovary cell lines resistant to mitomycin C under aerobic but not hypoxic conditions are deficient in DT-diaphorase. Cancer Res 51: 1860–1865, 1991
Begleiter A, Leith M, McClarty G, Beenken S, Goldenberg GJ, Wright JA: Characterization of L5178Y murine lymphoblasts resistant to quinone antitumor agents. Cancer Res 48: 1727–1735, 1988
Begleiter A, Robotham E, Lacey G, Leith MK: Increased sensitivity of quinone resistant cells to mitomycin C. Cancer Lett 45: 173–176, 1989
Siegel D, Gibson NW, Preusch PC, Ross D: Metabolism of mitomycin C by DT-diaphorase: role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res 50: 7483–7489, 1990
Traver RD, Horikoshi T, Danenberg KD, Stadlbauer THW, Danenberg PV, Ross D, Gibson NW: NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin C sensitivity. Cancer Res 52: 797–802, 1992
Ross D: DT-diaphorase in activation and detoxification of quinones. This volume
Pan S: The role of NAD(P)H:quinone oxidoreductase in mitomycin C and porfiromycin resistant human colon cancer HCT 116 cells. Proc Amer Assoc Cancer Res 33: 461, 1992
Robertson N, Stratford IJ, Houlbrook S, Carmichael J, Adams GE: The sensitivity of human tumor cells to quinone bioreductive drugs: What role for DT-diaphorase? Biochem Pharmac 44: 409–412, 1992
O'Dwyer PH, Perez RP, Clayton M, Goodwin AK, Hamilton TC: Increased DT-diaphorase activity and cross-resistance to mitomycin C (MMC) in a series of cisplatin-resistant human ovarian carcinoma cell lines. Proc Amer Assoc Cancer Res 33: 461, 1992
Hoban PR, Walton MI, Robson CN, Godden J, Stratford IJ, Workman P, Harris AL, Hickson ID: Decreased NADPH:cytochrome P-450 reductase activity and impaired drug activation in a mammalian cell line resistant to mitomycin C under aerobic but not hypoxic conditions. Cancer Res 50: 4692–4697, 1990
Gustafson DL, Pristos CA: Bioactivation of mitomycin C by xanthine dehydrogenase from EMT6 mouse mammary carcinoma tumors. J Nat Cancer Inst 84: 1180–1185, 1992
Talalay P, Benson AM: Elevation of quinone reductase activity by anticarcinogenic antioxidants. Adv Enz Regul 20: 287–300, 1982
Sun Y: Free radicals, antioxidant enzymes and carcinogenesis. Free Rad Biol Med 8: 583–599, 1990
Favreau LV, Pickett CB: Transcriptional regulation of the rat NAD(P)H:quinone reductase gene. J Biol Chem 266: 4556–4561, 1991
Marshall RS, Paterson MC, Rauth AM: DT-diaphorase activity and mitomycin C sensitivity in non-transformed cell strains derived from members of a cancer-prone family. Carcinogenesis 12: 1175–1180, 1990
Beyer RE, Segura-Aguilar J, Lind C, Castro VM: DT-diaphorase activity in various cells in culture emphasis on induction in ascites hepatoma cells. Chem Scr 27A: 145–150, 1987
Cresteil T, Jaiswal AK: High levels of expression of the NAD(P)H:quinone oxidoreductase (NQOI) gene in tumor cells compared to normal cells of the same origin. Biochemical Pharmacol 42: 1021–1027, 1991
Malkinson AM, Siegel D, Forrest GL, Grazdar AF, Oie HK, Chan DC, Bunn PA, Mabry M, Dykes DJ, Harrison Jr. SD, Ross D: Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin C. Cancer Res 52: 4752–4757, 1992
Bailey SM, Suggett N, Walton MI, Workman P: Structureactivity relationships for DT-diaphorase reduction of hypoxic cell directed agents: indolquinones and diaziridinyl benzoquinones. Int J Radiat Biol Phys 22: 649–653, 1992
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rauth, A.M., Marshall, R.S. & Kuehl, B.L. Cellular approaches to bioreductive drug mechanisms. Cancer Metast Rev 12, 153–164 (1993). https://doi.org/10.1007/BF00689807
Issue Date:
DOI: https://doi.org/10.1007/BF00689807